Kidney

BNC105P

Description: BNC105P is a vascular disrupting agent that inhibits tubulin polymerization, causing cell cycle arrest and disruption of the tumor vasculature. It is administered intravenously on days 1 and 8 of a 21 day cycle in combination with Everolimus in patients with metastatic clear cell renal carcinoma after progressing on prior tyrosine kinase inhibitors.

Type(s) of Cancer: Kidney

Study Phase(s): Phase I
Phase II

Contact: Epp Goodwin at (210) 450-5798

S0931

Description:

This Phase III study compares the recurrence-free survival as well as overall survival of patients with renal cell carcinoma receiving everolimus or placebo after full surgical resection and who have no residual or metastatic disease.

Type(s) of Cancer: Kidney

Study Phase(s): Phase III

Contact: Epp Goodwin at (210) 450-5798

SAHA+Hydroxychloroquine

Description:

SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors

Type(s) of Cancer: Kidney

Study Phase(s): Phase II

Contact: Epp Goodwin at (210) 450-5798

Tivozanib

Description:

Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor. Patients with renal cell carcinoma who have received no prior systemic therapy for mRCC will be randomized to receive Tivozanib or Sunitinib for 12 weeks after what they will cross over for the other study drug they did not receive during the first 12 weeks.

Type(s) of Cancer: Kidney

Study Phase(s): Phase II

Contact: Epp Goodwin at (210) 450-5798